common.study.topics.clinical

Long-Acting Naltrexone for Pre-Release Prisoners

common.study.values.description

Long-acting Naltrexone for Pre-release Prisoners

This proposed five-year study will focus on whether the addition of providing XR-NTX treatment at a patients' place of residence will increase adherence and thus efficacy of the medication.Following initial screening, informed consent, and medical examination, pre-release prisoners at each facility will be block randomized (N=240) within gender to either: Condition 1. XR-NTX-OTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at an opioid treatment program; or Condition 2. XR-NTX+MMTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at the patient's place of residence.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - XR-NTX

Vivitrol

place of residence

One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence

opioid treatment program

One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program

participant.views.study.view.additional

participant.views.study.view.scientific-title

Long-acting Naltrexone for Pre-release Prisoners: A Randomized Trial of Mobile Treatment

common.study.values.clinical-trial-id

NCT02867124

participant.views.study.view.id

9av55e